Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

  • Additional filter size for KadcylaSubscription

    The summary of product characteristics for Kadcyla (trastuzumab emtansine; Roche) has been revised to include recommendations on an additional filter size of 0.2 micron for in-line filtration during infusion using sodium chloride 0.9% as a solvent.

  • Contraindications with Ex-lax Senna PillsSubscription

    The summary of product characteristics (SPC) for Ex-lax Senna Pills (sennoside; Novartis) now states that the medicine is contradicted with irritation of the gastrointestinal tract, abdominal pain of unknown origin, severe dehydration states, especially hypokalaemia, and in children aged under 12 years. Patients taking cardiac glycosides, antiarrhythmic medicinal products, medicinal products inducing QT-prolongation, diuretics, adrenocorticosteroids or liquorice root, have to consult ...

  • Reduced efficacy of benzodiazepines with XenicalSubscription

    The summary of product characteristics for Xenical (orlistat; Roche) now states that there are some case reports of reduced efficacy of benzodiazepines coincidental to the initiation of orlistat treatment in previously well controlled patients. Therefore, orlistat treatment should only be initiated after careful consideration of the possible impact in these patients.

  • New indication for EyleaSubscription

    Eylea (aflibercept; Bayer) is now indicated for visual impairment due to myopic choroidal neovascularisation. Further changes to the summary of product characteristics reflect this addition. 

Other product updates

  • AWMSG November medicines approvalsSubscription

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Xultophy (insulin degludec and liraglutide) for use with oral antidiabetic drugs to treat adults with type 2 diabetes — it can only be used when oral treatments combined with basal insulin do not provide adequate glycaemic control; Fomicyt (fosfomycin) to treat acute osteomyelitis, complicated urinary tract infections, nosocomial lower respiratory tract infections or bacterial ...

  • New requirements for controlled drugsSubscription

    The Home Office has highlighted two changes affecting controlled drugs. First, from 30 November 2015, amendments to the Misuse of Drugs Regulations 2001 will make the use of an approved form for the requisitioning of Schedule 2 and 3 Controlled Drugs in the community mandatory. This applies to both requisitions for human and for veterinary use.

  • November 2015: SMC decisionsSubscription

    The Scottish Medicines Consortium has accepted the following medicines for use in NHS Scotland: atazanavir and cobicistat (Evotaz; Bristol-Myers Squibb); edoxaban (Lixiana; Daiichi Sankyo), for two separate indications; pembrolizumab (Keytruda; Merck Sharp and Dohme), as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab; tiotropium/olodaterol (Spiolto Respimat; Boehringer Ingelheim); and triamcinolone hexacetonide ...

  • Errors in the BNF for ChildrenSubscription

    An error has been found in the new British National Formulary (BNF) for Children (2015–2016) regarding the indications of aciclovir. Some indications are omitted or are unclear.

Other notifications

  • Non-medical prescribers websiteSubscription

    A new website called Prescribers SPaCE – Sharing Practice and Continuing Education – has been launched for non medical prescribers (NMPs) by the University Hospitals Birmingham NHS Foundation Trust and others. The website is intended to provide a forum for NMPs to to share ideas, evidence-based resources and good practice tools. 

  • Covert administration in care homes flowchartSubscription

    Aneurin Bevan University Health Board in Wales and the Cardiff School of Pharmacy and Pharmaceutical Sciences have developed a flowchart to inform decision making in care homes related to covert administration. The flowchart supports care home staff to differentiate between difficult to swallow and covert administration, and provides guidance for subsequent steps such as informing the multidisciplinary team and assessing residents for capacity.

  • How to use the BNFSubscription

    The Centre for Pharmacy Postgraduate Education (CPPE) has launched a new distance e-learning programme called ‘How to use the BNF’. The programme explores the recent changes in the structure of content in the British National Formulary (BNF). The programme can be accessed on the CPPE website. 

  • Sexual health learning programmeSubscription

    The Centre for Pharmacy Postgraduate Education (CPPE) has launched a new e-learning module called ‘Sexual health in pharmacies’. It is designed to help pharmacists and their teams deliver sexual health services. This programme replaces the ‘Sexual health in pharmacies: developing your service’ distance learning programme. The new programme can be accessed via ...

Other resources

  • The Great British Tea Party for European Antibiotic Awareness DaySubscription

    The charity Antibiotic Research UK is running a large fundraising and educational event, called the Great British Tea Party, to coincide with European Antibiotic Awareness Day on 18 November 2015. The charity will be providing organisers with information and materials about appropriate and inappropriate antibiotic use. Those ...

Other opportunities

  • Antimicrobial resistance strategy for veterinary medicinesSubscription

    The European Medicines Agency (EMA) has released for public consultation a new strategy on antimicrobial resistance addressing medicinal products for veterinary use. The consultation documents can be accessed on the

  • Dinutuximab not recommended in draft NICE guidanceSubscription

    The National Institute for Health and Care Excellence (NICE) has published draft guidance that does not recommend dinutuximab (when used in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and isotretinoin) as a treatment for high-risk neuroblastoma for children and young people between the ages of 12 months and 17 years.

  • Controlled drugs consultationSubscription

    The National Institute for Health and Care Excellence (NICE) has published a consultation on the safe use and management of controlled drugs. The consultation covers guidance on prescribing, obtaining and supplying, administering, handling, and recording and monitoring use of controlled drugs. It is available ...

  • NICE recommendations for juvenile idiopathic arthritisSubscription

    The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending abatacept (Orencia; Bristol-Myers Squibb), adalimumab (Humira; AbbVie), etanercept (Enbrel; Pfizer) and tocilizumab (RoActemra; Roche) as options for treating juvenile idiopathic arthritis. A consultation on the guidance, which is available from ...

Other consultations

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

Pharmaceutical Journal Jobs

More jobs